During this almost two week period, I was able to cut my inhaled steroid dosage in half, and I wheezed and coughed less. This discovery motivated me to search the web for keywords "asthma" and "azithromycin" (azithromycin is the generic name of Zithromax, which is sold exclusively by Pfizer in the U. S.: I presented some of the research that Jim Quinlan has assembled (Asthma cure research page from asthmastory.com) to two physicians (both Internists, one my physician, the other my brother-in-law) who both said that this treatment would not improve my asthma. 4 puffs twice daily of the strongest 220 mcg Flovent (the absolute maximum recommended dosage), 2 puffs twice daily of Serevent, Singulair once daily, albuterol inhaler as needed, theophylline as needed, and an occasional nebulizer treatment with albuterol. Over the years that I had been taking inhaled steroids (e.g., Flovent), I kept increasing the dosage as the asthma seemed to get worse and worse, until I finally reached the absolute maximum recommended dosage. After six weeks of this, my asthma was so much better that I was able to completely stop my Flovent, Serevent, and Singulair, and I only needed to take an albuterol inhaler occasionally (less than one puff per week). Even if your asthma is worsened by a persistent bacterial infection, you may need to pursue a treatment that involves antibiotic(s) other than azithromycin, and the treatment may last longer than nine to fifteen weeks. Condition(s) targeted: Asthma Intervention: Zithromax (Drug); Placebo (Drug) Phase: Phase 4 Status: Completed Sponsored by: Imperial College London Official(s) and/or principal investigator(s): Sebastian L Johnston, MBBS, Ph D, FRCP, Study Chair, Affiliation: Imperial College London Acute attacks (exacerbations) of asthma are common and cause a great deal of suffering in asthmatic patients. Current treatments for asthma attacks are not completely effective and new and better treatments are needed. Viruses often cause asthma attacks and bacterial lung infections have also been associated with asthma attacks. Current asthma guidelines for doctors treating asthma exacerbations do not recommend the routine use of antibiotics. The investigators would like to investigate whether or not azithromycin, which is a safe and well tolerated antibiotic (an antibacterial) that has been used for many years in the treatment of respiratory disease, might be of benefit in asthma attacks. As there is some evidence that azithromycin has anti-viral properties this may add to its benefits (antibiotics don't usually affect viruses). By looking at the effect of azithromycin on asthma attacks this will help us to show whether or not azithromycin should be recommended during an acute asthma attack in addition to the usual care that is provided to these patients as it may help them recover quicker from the exacerbation. The investigators will also be able to look at why azithromycin may be effective - if it is having an anti-bacterial and/or anti-viral effect.
Обычная практика: 1 таблетка в дозе 500 мг х 1 раз в день в течение 3 - х дней, иногда до 5 дней. Этот препарат хорошо сочетается с антибиотиками цефалоспоринового ряда: Цефтриаксон по 1 грамму х 1 раз в день - 5 дней внутримышечно или внутривенно капельно или струйно. Саму бронхиальную астму антибиотиками не лечат, применяется "золотой стандарт" в виде ингаляционных кортикостероидов в сочетании с короткодействующими ингаляторами для контроля за течением заболевания, ибо это самый короткий путь к больному органу. Все препараты в виде ингаляторов или через небулайзер. При бронхиальной астме антибиотики назначают, если есть обострение сопутствующего хронического бронхита (ХОБЛ) или пневмонии. Об азитромицине, как антибиотике при лечении бронхолёгочных заболеваний, у, меня лично хорошее мнение. Когда то, мне очень хорошо и быстро помог справиться с трахеобронхитом и тонзиллитом, ещё в 2014 г. У каждого врача, есть круг любимых препаратов, которые когда то помогли самому, при различных заболеваниях. Сдается мне, что, у, вас присутствует обострение хронического бронхита с астматическим компонентом. Элементы бронхиальной астмы имеют инфекционно-аллергическую основу. Не думаю, что азитромицин вызовет, у, вас, что-то аллергическое, но, на всякий случай совместно с ним, следует прикрыться, каким-нибудь антигистаминным средством, тем же диазолином. JAMAJAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Facial Plastic Surgery JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) A and B, Acute and Mini AQLQ mean scores by visits for each treatment arm. C, Kaplan-Meier curves of time to a 50% reduction in symptom diary score for each treatment arm (truncated at 10 days).e Methodse Resultse Figures 1-2. Observed mean symptom scores for each day by treatment group and their standard deviatione Table 2. Detailed statistics of observed diary scorese Table 3. Estimated difference in change of diary scores from baseline and 95% confidence intervals for azithromycin compared to the placeboe Figure 3. Observed mean (SD) pulmonary function test results by visit and treatment arme Table 12. Boxplot of residuals for linear and quadratic modelse Table 4. Estimates of pulmonary function mean differencese Tables 13-15. Estimated Day 10 difference in change of diary scores from baseline for subgroupse Figures 6-8. Observed mean diary scores and standard errors of subgroups by treatment arme Table 16. Number of adverse events by SOC category and treatment arme Table 17.
Background Patients with severe asthma are at increased risk of exacerbations and lower respiratory tract infections (LRTI). Severe asthma is heterogeneous, encompassing eosinophilic and non-eosinophilic (mainly neutrophilic) phenotypes. Patients with neutropilic airway diseases may benefit from macrolides. Methods We performed a randomised double-blind placebo-controlled trial in subjects with exacerbation-prone severe asthma. Subjects received low-dose azithromycin (n=55) or placebo (n=54) as add-on treatment to combination therapy of inhaled corticosteroids and long-acting β agonists for 6 months. The primary outcome was the rate of severe exacerbations and LRTI requiring treatment with antibiotics during the 26-week treatment phase. Secondary efficacy outcomes included lung function and scores on the Asthma Control Questionnaire (ACQ) and Asthma Quality of Life Questionnaire (AQLQ). , it found that azithromycin add-on therapy reduces exacerbation frequency and improves quality of life in asthmatic patients. There is currently a strong need to prevent asthma exacerbation in patients with uncontrolled asthma. Many new biological medications have come on the market recently to treat this segment of the population. All of them come with a heavy price tag and may not be feasible for all patients with severe persistent asthma. New Asthma Drug Nucala (Mepolizumab) for Severe Eosinophilic Asthma Cinqair (Reslizumab) for Eosinophil Disorders (formerly Cinquil) Fasenra (Benralizumab) for Severe Asthma A randomized trial looked at adding the antibiotic azithromycin (this antibiotic is commonly known as Z-pack) for patients with severe asthma that was uncontrolled by inhaled corticosteroids and long acting bronchodilators. They were either assigned to receive 500mg of azithromycin 3 times per week or a placebo for 48 weeks. Azithromycin treatment decreased the frequency of all asthma exacerbations and severe exacerbations.
Nov 26, 2017. Asthma costs the US health care system roughly 50 billion dollars annually.1 And patients with uncontrolled severe asthma 2 exacerbations. Sep 19, 2016. This randomized clinical trial examines whether azithromycin added to standard care for asthma attacks in adults results in clinical benefit.